Microbot Medical's LIBERTY robotic system gains commercial adoption, expanding globally after clinical trial success.

Microbot Medical Inc. has achieved commercial adoption of its LIBERTY Endovascular Robotic System by multiple accounts, including two that participated in the ACCESS-PVI pivotal clinical trial. This adoption follows the system's full market release and is supported by updated medical guidelines promoting reduced radiation exposure and better ergonomics. The company plans to boost its global presence at the upcoming GEST conference in New York and expand international sales with a new VP of Sales for EMEA. These steps aim to grow Microbot's footprint in endovascular robotic technology and improve interventional care worldwide.